This site is fictional demo content. It is not real news or affiliated with any real organization. Do not treat it as fact or professional advice.

NextPaper Logo
nextpaper.ccCYBER CHRONICLE
RSS
EN中文

Full article

FULL TEXT

View this issue
Deep diveMEDTECH

Organ-on-a-Chip Gains FDA Approval to Replace Animal Testing: Dual Breakthrough in Drug Development Ethics and Efficiency

FDA has formally approved organ-on-a-chip data as supporting evidence for IND applications, no longer mandating specific animal studies. Emulate's human-on-a-chip platform has been adopted by Pfizer and Johnson & Johnson.

Organ-on-a-Chip Gains FDA Approval to Replace Animal Testing

On February 10, 2028, the FDA issued a final rule formally approving organ-on-a-chip data as supporting evidence for Investigational New Drug (IND) applications. Under specified conditions, pharmaceutical companies may substitute traditional animal toxicology studies with organ-on-a-chip experiments.

"This decision is grounded in years of scientific validation," said FDA Commissioner Robert Califf. "Organ-on-a-chip accuracy in predicting human responses now surpasses traditional animal models."

Background

Organ-on-a-chip devices are microfluidic platforms that culture human cells to replicate real organ structure and function. A chip the size of a postage stamp contains hundreds of thousands of living cells, with microchannels delivering nutrients and drugs to reproduce organ-level physiological responses.

Emulate, the sector leader, offers liver, kidney, gut, lung, and brain chips plus a multi-organ "human-on-a-chip" system connecting them. "A human-on-a-chip system can generate in two weeks what takes six months in animal studies, with higher predictive accuracy," said Emulate CEO Jim Corbett.

Supporting Data

The FDA's decision was based on multiple head-to-head studies. The largest, led by Janssen, compared rat studies versus liver chip predictions across 50 known toxic compounds:

  • Liver chip: 91% sensitivity, 87% specificity, 89% overall accuracy
  • Rat study: 65% sensitivity, 73% specificity, 68% overall accuracy

Industry Impact

Pfizer has announced plans to shift 30% of preclinical safety assessments to organ-on-chip by end of 2028. Amgen and Bristol-Myers Squibb have announced similar transitions.

Animal welfare organizations welcomed the decision. The Humane Society's chief scientist stated: "Approximately 100 million animals are used in drug testing globally each year. Organ-on-chip adoption could reduce this number by over 50% within a decade."

Limitations

Current chips cannot fully replicate systemic immune responses or long-term chronic toxicity. Manufacturing costs remain high at $500-1,000 per chip. The FDA emphasizes that organ-on-chip data currently serves as "supporting evidence" rather than complete replacement.

Future Directions

The FDA plans to publish detailed technical guidance for organ-on-chip data by end of 2028. Emulate is developing "immune chips" and "placenta chips" for commercial release in 2029.